Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2019 Nov 27;6222:10376-10390. doi: 10.1021/acs.jmedchem.9b01467.
Show Gene links
Show Anatomy links
Synthesis, Pharmacological Characterization, and Structure-Activity Relationships of Noncanonical Selective Agonists for α7 nAChRs.
Camacho-Hernandez GA
,
Stokes C
,
Duggan BM
,
Kaczanowska K
,
Brandao-Araiza S
,
Doan L
,
Papke RL
,
Taylor P
.
???displayArticle.abstract???
A lack of selectivity of classical agonists for the nicotinic acetylcholine receptors (nAChR) has prompted us to identify and develop a distinct scaffold of α7 nAChR-selective ligands. Noncanonical 2,4,6-substituted pyrimidine analogues were framed around compound 40 for a structure-activity relationship study. The new lead compounds activate selectively the α7 nAChRs with EC50's between 30 and 140 nM in a PNU-120596-dependent, cell-based calcium influx assay. After characterizing the expanded lead landscape, we ranked the compounds for rapid activation using Xenopus oocytes expressing human α7 nAChR with a two-electrode voltage clamp. This approach enabled us to define the molecular determinants governing rapid activation, agonist potency, and desensitization of α7 nAChRs after exposure to pyrimidine analogues, thereby distinguishing this subclass of noncanonical agonists from previously defined types of agonists (agonists, partial agonists, silent agonists, and ago-PAMs). By NMR, we analyzed pKa values for ionization of lead candidates, demonstrating distinctive modes of interaction for this landscape of ligands.
???displayArticle.pubmedLink???
31675224
???displayArticle.pmcLink???PMC7768633 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Arunrungvichian,
Selectivity optimization of substituted 1,2,3-triazoles as α7 nicotinic acetylcholine receptor agonists.
2015, Pubmed
Arunrungvichian,
Selectivity optimization of substituted 1,2,3-triazoles as α7 nicotinic acetylcholine receptor agonists.
2015,
Pubmed
Bagdas,
New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.
2018,
Pubmed
Beers,
Structure and activity of acetylcholine.
1970,
Pubmed
Bertrand,
Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors.
2015,
Pubmed
Bezençon,
pKa determination by ¹H NMR spectroscopy - an old methodology revisited.
2014,
Pubmed
Bordia,
Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
2007,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Changeux,
The nicotinic acetylcholine receptor: a typical 'allosteric machine'.
2018,
Pubmed
Corradi,
Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery.
2016,
Pubmed
Dziewczapolski,
Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease.
2009,
Pubmed
Esterhuysen,
Trifluoromethyl: An Amphiphilic Noncovalent Bonding Partner.
2017,
Pubmed
Freedman,
Initial phase 2 trial of a nicotinic agonist in schizophrenia.
2008,
Pubmed
Gill-Thind,
Structurally similar allosteric modulators of α7 nicotinic acetylcholine receptors exhibit five distinct pharmacological effects.
2015,
Pubmed
,
Xenbase
Gillis,
Applications of Fluorine in Medicinal Chemistry.
2015,
Pubmed
Gulsevin,
Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site.
2019,
Pubmed
,
Xenbase
Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase
Hauser,
TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
2009,
Pubmed
Horenstein,
Anti-inflammatory Silent Agonists.
2017,
Pubmed
Horenstein,
Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.
2016,
Pubmed
,
Xenbase
Horenstein,
Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.
2008,
Pubmed
,
Xenbase
Hoskin,
Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update.
2019,
Pubmed
Jones,
Nicotinic receptors in the brain: correlating physiology with function.
1999,
Pubmed
Kaczanowska,
Substituted 2-Aminopyrimidines Selective for α7-Nicotinic Acetylcholine Receptor Activation and Association with Acetylcholine Binding Proteins.
2017,
Pubmed
Kaczanowska,
Structural basis for cooperative interactions of substituted 2-aminopyrimidines with the acetylcholine binding protein.
2014,
Pubmed
Kalkman,
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders.
2016,
Pubmed
Kem,
The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
2000,
Pubmed
Kerns,
High throughput physicochemical profiling for drug discovery.
2001,
Pubmed
Lipinski,
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
2001,
Pubmed
MacDermott,
Presynaptic ionotropic receptors and the control of transmitter release.
1999,
Pubmed
Mazurov,
Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.
2012,
Pubmed
Müller,
Fluorine in pharmaceuticals: looking beyond intuition.
2007,
Pubmed
Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase
Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase
Papke,
Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses.
2006,
Pubmed
,
Xenbase
Papke,
The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.
2014,
Pubmed
,
Xenbase
Prickaerts,
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
2012,
Pubmed
Quadri,
Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation.
2017,
Pubmed
,
Xenbase
Quik,
Nicotine and nicotinic receptors; relevance to Parkinson's disease.
2002,
Pubmed
Schiebel,
Charges Shift Protonation: Neutron Diffraction Reveals that Aniline and 2-Aminopyridine Become Protonated Upon Binding to Trypsin.
2017,
Pubmed
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Umbricht,
A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
2014,
Pubmed
Veber,
Molecular properties that influence the oral bioavailability of drug candidates.
2002,
Pubmed
Wallace,
RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
2011,
Pubmed
,
Xenbase
Yamauchi,
Characterizing ligand-gated ion channel receptors with genetically encoded Ca2++ sensors.
2011,
Pubmed
Young,
Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
2008,
Pubmed
,
Xenbase
Zhong,
From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor.
1998,
Pubmed
Zhou,
Human alpha4beta2 acetylcholine receptors formed from linked subunits.
2003,
Pubmed
,
Xenbase
de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed
